Login / Signup

Biostimulant Activity of Silicate Compounds and Antagonistic Bacteria on Physiological Growth Enhancement and Resistance of Banana to Fusarium Wilt Disease.

Md Aiman Takrim ZakariaSiti Zaharah SakiminMohd Razi IsmailKhairulmazmi AhmadSusilawati KasimAli Baghdadi
Published in: Plants (Basel, Switzerland) (2023)
Biostimulants such as silicate (SiO 3 2- ) compounds and antagonistic bacteria can alter soil microbial communities and enhance plant resistance to the pathogens and Fusarium oxysporum f. sp. cubense (FOC), the causal agent of Fusarium wilt disease in bananas. A study was conducted to investigate the biostimulating effects of SiO 3 2- compounds and antagonistic bacteria on plant growth and resistance of the banana to Fusarium wilt disease. Two separate experiments with a similar experimental setup were conducted at the University of Putra Malaysia (UPM), Selangor. Both experiments were arranged in a split-plot randomized complete block design (RCBD) with four replicates. SiO 3 2- compounds were prepared at a constant concentration of 1%. Potassium silicate (K 2 SiO 3 ) was applied on soil uninoculated with FOC, and sodium silicate (Na 2 SiO 3 ) was applied to FOC-contaminated soil before integrating with antagonistic bacteria; without Bacillus spp. ((0B)-control), Bacillus subtilis (BS), and Bacillus thuringiensis (BT). Four levels of application volume of SiO 3 2- compounds [0, 20, 40, 60 mL) were used. Results showed that the integration of SiO 3 2- compounds with BS (10 8 CFU mL -1 ) enhanced the physiological growth performance of bananas. Soil application of 28.86 mL of K 2 SiO 3 with BS enhanced the height of the pseudo-stem by 27.91 cm. Application of Na 2 SiO 3 and BS significantly reduced the Fusarium wilt incidence in bananas by 56.25%. However, it was recommended that infected roots of bananas should be treated with 17.36 mL of Na 2 SiO 3 with BS to stimulate better growth performance.
Keyphrases
  • magnetic nanoparticles
  • plant growth
  • bacillus subtilis
  • body mass index
  • randomized controlled trial
  • open label
  • risk factors
  • study protocol
  • phase iii
  • genetic diversity